Knowledge Tree
ibogaine
Facts (25)
Sources
Effects of psychedelics on neurogenesis and broader neuroplasticity link.springer.com Dec 19, 2024 9 facts
measurementThree hours post-injection, ibogaine caused a 1.7-fold and 2-fold decline in prefrontal cortex (PFC) BDNF mRNA for the 20 mg/kg and 40 mg/kg dosage groups, respectively, as reported by Marton et al. (2019).
claimPsychoactive tryptamines, including psilocybin, DMT, and ibogaine, enhance neuroplasticity by promoting the proliferation, migration, and differentiation of neurons.
measurementA 40 mg/kg dose of ibogaine elevated GDNF levels in the ventral tegmental area (VTA) and substantia nigra (SN) of rat brains 24 hours post-injection, according to Marton et al. (2019).
claimIbogaine is a naturally occurring psychoactive tryptamine found in certain plants of the Apocynaceae family native to Central Africa and has been investigated for its potential to mitigate drug-seeking behavior.
measurementA review of eleven studies on psychoactive tryptamines found that 18% investigated psilocybin, 9% investigated ibogaine, and 73% investigated DMT analogs, including ayahuasca.
measurementIbogaine treatment (at both 20 mg/kg and 40 mg/kg) resulted in the upregulation of proBDNF protein in the nucleus accumbens (NAcc) and GDNF protein in the ventral tegmental area (VTA) exclusively for the 40 mg/kg dose, as observed by Marton et al. (2019).
referenceAlper, Lotsof, and Kaplan (2008) documented the medical subculture surrounding the use of ibogaine.
measurementIbogaine administration at doses of 20 mg/kg and 40 mg/kg dose-dependently upregulated BDNF and NGF mRNA in the prefrontal cortex (PFC), ventral tegmental area (VTA), substantia nigra (SN), and nucleus accumbens (NAcc) of rat brains 24 hours post-injection, according to Marton et al. (2019).
claimIbogaine administration modifies GDNF and BDNF expression in brain regions involved in mesocorticolimbic and nigral dopaminergic circuits.
Neuroimaging in psychedelic drug development: past, present, and ... nature.com Sep 27, 2023 4 facts
claimWhile the authors focused their study outlines on 5-HT2AR agonist 'classic' psychedelics like psilocybin, LSD, and DMT, these study frameworks could be applied to other novel therapies such as ketamine, MDMA, and ibogaine.
measurementAs of the time of writing, there are 96 registered clinical trials for psilocybin, 112 for MDMA, 132 for LSD, 20 for Dimethyltryptamine, and 4 for ibogaine listed on clinicaltrials.gov.
claimKetamine, 3,4-Methylenedioxymethamphetamine (MDMA), and ibogaine are psychoactive substances that hold promise for psychiatric treatment alongside classic serotonergic psychedelics.
claimModern research into classic psychedelics and related compounds includes the study of LSD, psilocybin, N,N-Dimethyltryptamine (DMT), MDMA, ketamine, and ibogaine.
the consumption of psychoactive plants in ancient global and ... academia.edu 4 facts
referenceMaciulaitis R, Kontrimaviciute V, Bressolle FM, and Briedis V authored 'Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review', published in Human & Experimental Toxicology in 2008.
claimPsychoactive ingredients used in religious rituals include narcotic analgesics (opium), THC (cannabis), psilocybin (magic mushrooms), mescaline (peyote), ibogaine (Tabernanthe iboga), DMT (Ayahuasca and phalaris species), Peganum harmala, bufotenin, muscimol (Amanita muscaria), thujone (absinthe, Arthemisia absinthium), ephedra, mandragora, star lotus, and Salvia divinorum.
referenceThe article "100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug" was published in the journal Pharmacological Reviews in 1995, volume 47, issue 2, pages 235-253.
claimCommon psychoactive ingredients historically used include psilocybin, THC, and ibogaine, which have influenced psychological and philosophical perspectives.
Published Studies — Johns Hopkins Center for Psychedelic and ... hopkinspsychedelic.org 3 facts
referenceA 2018 study by Davis, Renn, Windham-Herman, Polanco, and Barsuglia performed a mixed-method analysis of persisting effects associated with positive outcomes following ibogaine detoxification.
referenceA 2023 open-label study by Davis, Xin, Sepeda, and Averill published in 'The American Journal of Drug and Alcohol Abuse' analyzed prospective data from a clinical program in Mexico involving consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces veterans.
referenceA 2017 study by Davis, Barsuglia, Windham-Herman, Lynch, and Polanco published in the Journal of Psychedelic Studies examined the subjective effectiveness of ibogaine treatment for problematic opioid consumption, including short- and long-term outcomes and current psychological functioning.
The Montreal model: an integrative biomedical-psychedelic ... frontiersin.org 2 facts
claimWhile some experts define the term 'psychedelic' specifically as agonists of serotonin 2A receptors (such as psilocybin), psychedelic treatment models have been applied to diverse psychoactive drugs including MDMA, ibogaine, cannabis, and ketamine.
referenceBrown and Alper (2017) studied the use of ibogaine for the treatment of opioid use disorder, specifically examining detoxification and drug use outcomes.
Psychedelic Drugs News - ScienceDaily sciencedaily.com 1 fact
claimResearchers achieved total chemical synthesis of the psychoactive compound ibogaine and its analogs starting from pyridine, which facilitates the exploration of its therapeutic possibilities.
History and Current Status of Psychedelics and Entactogens ... - NCBI ncbi.nlm.nih.gov 1 fact
claimNon-classic hallucinogens include MDMA (also known as ecstasy or molly), ketamine, and ibogaine, according to Charles Grob.
Psychedelics, Sociality, and Human Evolution frontiersin.org 1 fact
referenceThe Fang people of West Africa utilize Tabernanthe iboga (common name: eboka), which contains the psychoactive principles ibogaine and ibogamine (Rätsch, 2005).